奧密克戎亞型變異株BQ.1及其子毒株——免疫逃避能力最強(qiáng)的BQ.1.1——正在美國肆虐。
根據(jù)美國疾病控制與預(yù)防中心上周五發(fā)布的最新預(yù)測(cè),這兩者的感染病例占美國確診病例的11%以上。美國疾病控制與預(yù)防中心在此之前沒有列出這些變體,因?yàn)楣烙?jì)這兩者在流行變體中所占比例不到1%。此前,這兩者被列在母株BA.5譜系下。
這兩者結(jié)合起來,只差不到一個(gè)百分點(diǎn)就能登上全國第二的寶座,目前該寶座由BA.4.6占據(jù),估計(jì)BA.4.6的感染病例占美國確診病例的12.2%。此前占據(jù)主導(dǎo)地位的變體BA.5的感染病例正在下降,截至周五,估計(jì)占美國確診病例的70%以下。
美國基因組監(jiān)測(cè)的重要更新,隨著BA.5的消退,BQ.1.1以及其他變體(BF.7,BA.2.75.2)快速傳播,這是值得關(guān)注的轉(zhuǎn)變。https://t.co/jjl2AnwOWX pic.twitter.com/FuXdB42QuM
- 埃里克·托普爾(Eric Topol)(@EricTopol)2022年10月14日
美國頂級(jí)傳染病專家、總統(tǒng)首席醫(yī)療顧問安東尼·福奇(Anthony Fauci)博士周五告訴美國哥倫比亞廣播公司新聞(CBS News):“當(dāng)這樣的變體出現(xiàn)時(shí),你要看相對(duì)而言,它們的增長速度在變體中的比例是多少,這是一個(gè)相當(dāng)麻煩的倍增時(shí)間?!?/p>
紐約BQ.1.1感染病例激增,專家認(rèn)為紐約是一個(gè)“風(fēng)向標(biāo)”州,因?yàn)樗写罅咳刖车膰H旅客和強(qiáng)大的基因測(cè)序能力。BQ.1.1感染病例在德國等歐洲國家也在上升,慕尼黑啤酒節(jié)的慶?;顒?dòng)可能已造成超級(jí)傳播。
據(jù)斯克利普斯研究所(Scripps Research)的分子醫(yī)學(xué)教授、斯克利普斯研究轉(zhuǎn)化研究所(Scripps Research Translational Institute)的創(chuàng)始人兼主任埃里克·托普爾(Eric Topol)博士說,BQ.1.1與XBB變體(合并了兩種不同奧密克戎變異株,在新加坡和孟加拉國肆虐),被認(rèn)為是免疫逃避能力最強(qiáng)的新變體。
托普爾周五在推特上寫道,BQ.1.1的超強(qiáng)免疫逃避能力“將使其成為未來幾周美國下一波疫情的主要背后推手”。
周四,他告訴《財(cái)富》雜志,如果BQ.1.1可以逃避疫苗提供的免疫保護(hù)的話,直到某個(gè)地方的感染病例達(dá)到30%-50%,科學(xué)家們才會(huì)知道BQ.1.1在多大程度上可以逃避疫苗提供的免疫保護(hù)。
他說:“這不會(huì)抹殺疫苗的效力,但在預(yù)防住院和死亡方面可能會(huì)有所削弱?!?/p>
已知BQ.1.1能逃避抗體免疫,這使得在新冠高危人群中使用單克隆抗體治療無效。根據(jù)北京大學(xué)生物醫(yī)學(xué)創(chuàng)新中心上個(gè)月的一項(xiàng)研究,BQ.1.1逃避了對(duì)所有變體都有效的單克隆抗體藥物Bebtelovimab及另一種僅對(duì)某些變體起作用的抗體藥物Evusheld提供的免疫保護(hù)。作者寫道,BQ.1.1和CA.1和XBB變體一起可能導(dǎo)致更嚴(yán)重的癥狀。
托普爾說應(yīng)該賦予BQ.1.1和 XBB變體新的希臘字母名稱,如派(Pi)或柔(Rho),因?yàn)檫@兩者與BA.5(它們的母株)差別很大。他還說就他而言,他本想給BA.5指定一個(gè)希臘字母名稱,因?yàn)樗c早代毒株BA.1和BA.2明顯不同。
福奇在周五接受美國哥倫比亞廣播公司(CBS)采訪時(shí)表示,如果說有好消息的話,那么關(guān)于BQ.1和BQ.1.1的好消息是,新的奧密克戎加強(qiáng)針“幾乎肯定”會(huì)針對(duì)這兩者提供“一定程度的”保護(hù),因?yàn)樗鼈兪轻槍?duì)BA.5的近親研發(fā)的。
根據(jù)加拿大安大略省公共衛(wèi)生部門10月5日的風(fēng)險(xiǎn)評(píng)估,BQ.1和BQ.1.1首次被檢測(cè)到是在7月中旬。加拿大安大略省公共衛(wèi)生部門將BQ.1和BQ.1.1的傳播性增強(qiáng)、再感染和預(yù)防感染的疫苗接種效力降低的風(fēng)險(xiǎn)水平評(píng)為高,這有極大的不確定性。
包括華盛頓大學(xué)衛(wèi)生計(jì)量與評(píng)估研究所的專家和福奇在內(nèi)的一些專家預(yù)測(cè),本月將出現(xiàn)新一輪疫情,感染病例激增,并在12月底或1月初達(dá)到峰值。
截至周四,向美國疾病控制與預(yù)防中心報(bào)告的七天平均確診病例數(shù)略低于每天38,000例。由于檢測(cè)處于歷史最低水平,人們普遍認(rèn)為,向該機(jī)構(gòu)報(bào)告的病例數(shù),以及該機(jī)構(gòu)報(bào)告的病例數(shù),與美國的實(shí)際病例數(shù)相比,顯得微不足道。(財(cái)富中文網(wǎng))
譯者:中慧言-王芳
奧密克戎亞型變異株BQ.1及其子毒株——免疫逃避能力最強(qiáng)的BQ.1.1——正在美國肆虐。
根據(jù)美國疾病控制與預(yù)防中心上周五發(fā)布的最新預(yù)測(cè),這兩者的感染病例占美國確診病例的11%以上。美國疾病控制與預(yù)防中心在此之前沒有列出這些變體,因?yàn)楣烙?jì)這兩者在流行變體中所占比例不到1%。此前,這兩者被列在母株BA.5譜系下。
這兩者結(jié)合起來,只差不到一個(gè)百分點(diǎn)就能登上全國第二的寶座,目前該寶座由BA.4.6占據(jù),估計(jì)BA.4.6的感染病例占美國確診病例的12.2%。此前占據(jù)主導(dǎo)地位的變體BA.5的感染病例正在下降,截至周五,估計(jì)占美國確診病例的70%以下。
美國基因組監(jiān)測(cè)的重要更新,隨著BA.5的消退,BQ.1.1以及其他變體(BF.7,BA.2.75.2)快速傳播,這是值得關(guān)注的轉(zhuǎn)變。https://t.co/jjl2AnwOWX pic.twitter.com/FuXdB42QuM
- 埃里克·托普爾(Eric Topol)(@EricTopol)2022年10月14日
美國頂級(jí)傳染病專家、總統(tǒng)首席醫(yī)療顧問安東尼·福奇(Anthony Fauci)博士周五告訴美國哥倫比亞廣播公司新聞(CBS News):“當(dāng)這樣的變體出現(xiàn)時(shí),你要看相對(duì)而言,它們的增長速度在變體中的比例是多少,這是一個(gè)相當(dāng)麻煩的倍增時(shí)間?!?/p>
紐約BQ.1.1感染病例激增,專家認(rèn)為紐約是一個(gè)“風(fēng)向標(biāo)”州,因?yàn)樗写罅咳刖车膰H旅客和強(qiáng)大的基因測(cè)序能力。BQ.1.1感染病例在德國等歐洲國家也在上升,慕尼黑啤酒節(jié)的慶祝活動(dòng)可能已造成超級(jí)傳播。
據(jù)斯克利普斯研究所(Scripps Research)的分子醫(yī)學(xué)教授、斯克利普斯研究轉(zhuǎn)化研究所(Scripps Research Translational Institute)的創(chuàng)始人兼主任埃里克·托普爾(Eric Topol)博士說,BQ.1.1與XBB變體(合并了兩種不同奧密克戎變異株,在新加坡和孟加拉國肆虐),被認(rèn)為是免疫逃避能力最強(qiáng)的新變體。
托普爾周五在推特上寫道,BQ.1.1的超強(qiáng)免疫逃避能力“將使其成為未來幾周美國下一波疫情的主要背后推手”。
周四,他告訴《財(cái)富》雜志,如果BQ.1.1可以逃避疫苗提供的免疫保護(hù)的話,直到某個(gè)地方的感染病例達(dá)到30%-50%,科學(xué)家們才會(huì)知道BQ.1.1在多大程度上可以逃避疫苗提供的免疫保護(hù)。
他說:“這不會(huì)抹殺疫苗的效力,但在預(yù)防住院和死亡方面可能會(huì)有所削弱?!?/p>
已知BQ.1.1能逃避抗體免疫,這使得在新冠高危人群中使用單克隆抗體治療無效。根據(jù)北京大學(xué)生物醫(yī)學(xué)創(chuàng)新中心上個(gè)月的一項(xiàng)研究,BQ.1.1逃避了對(duì)所有變體都有效的單克隆抗體藥物Bebtelovimab及另一種僅對(duì)某些變體起作用的抗體藥物Evusheld提供的免疫保護(hù)。作者寫道,BQ.1.1和CA.1和XBB變體一起可能導(dǎo)致更嚴(yán)重的癥狀。
托普爾說應(yīng)該賦予BQ.1.1和 XBB變體新的希臘字母名稱,如派(Pi)或柔(Rho),因?yàn)檫@兩者與BA.5(它們的母株)差別很大。他還說就他而言,他本想給BA.5指定一個(gè)希臘字母名稱,因?yàn)樗c早代毒株BA.1和BA.2明顯不同。
福奇在周五接受美國哥倫比亞廣播公司(CBS)采訪時(shí)表示,如果說有好消息的話,那么關(guān)于BQ.1和BQ.1.1的好消息是,新的奧密克戎加強(qiáng)針“幾乎肯定”會(huì)針對(duì)這兩者提供“一定程度的”保護(hù),因?yàn)樗鼈兪轻槍?duì)BA.5的近親研發(fā)的。
根據(jù)加拿大安大略省公共衛(wèi)生部門10月5日的風(fēng)險(xiǎn)評(píng)估,BQ.1和BQ.1.1首次被檢測(cè)到是在7月中旬。加拿大安大略省公共衛(wèi)生部門將BQ.1和BQ.1.1的傳播性增強(qiáng)、再感染和預(yù)防感染的疫苗接種效力降低的風(fēng)險(xiǎn)水平評(píng)為高,這有極大的不確定性。
包括華盛頓大學(xué)衛(wèi)生計(jì)量與評(píng)估研究所的專家和福奇在內(nèi)的一些專家預(yù)測(cè),本月將出現(xiàn)新一輪疫情,感染病例激增,并在12月底或1月初達(dá)到峰值。
截至周四,向美國疾病控制與預(yù)防中心報(bào)告的七天平均確診病例數(shù)略低于每天38,000例。由于檢測(cè)處于歷史最低水平,人們普遍認(rèn)為,向該機(jī)構(gòu)報(bào)告的病例數(shù),以及該機(jī)構(gòu)報(bào)告的病例數(shù),與美國的實(shí)際病例數(shù)相比,顯得微不足道。(財(cái)富中文網(wǎng))
譯者:中慧言-王芳
Omicron spawn BQ.1 and its offspring—the highly immune-evasive BQ.1.1—are coming in hot in the U.S.
The duo comprises more than 11% of COVID cases, according to updated projections released Friday by the U.S. Centers for Disease Control and Prevention. The agency hadn’t listed the variants until then because they were estimated to comprise less than 1% of those circulating. Previously, they had been reported under parent lineage BA.5.
Combined, the two are less than one percentage point away from taking the No. 2 spot in the nation, currently held by BA.4.6, estimated to comprise 12.2% of cases. Cases of leading variant BA.5 are on the decline, estimated to comprise less than 70% of cases as of Friday.
Important update of US genomic surveillance with noteworthy transition as BA.5 fades, BQ.1.1 quickly gains, along with other variants (BF.7, BA.2.75.2).https://t.co/jjl2AnwOWX pic.twitter.com/FuXdB42QuM
— Eric Topol (@EricTopol) October 14, 2022
“When you get variants like that, you look at what their rate of increase is as a relative proportion of the variants, and this has a pretty troublesome doubling time,” Dr. Anthony Fauci, the nation’s top infectious disease expert and the president’s chief medical adviser, told CBS News on Friday.
BQ.1.1 is surging in New York, considered by experts to be a “bellwether” state due to its volume of incoming international travelers and robust sequencing capabilities. It’s also rising in European countries like Germany, where Oktoberfest celebrations may have served as super-spreader events.
Along with XBB—a combination of two Omicron strains spiking in Singapore and Bangladesh—BQ.1.1 is thought to be the most immune-evasive new variant, according to Dr. Eric Topol, a professor of molecular medicine at Scripps Research and founder and director of the Scripps Research Translational Institute.
BQ.1.1’s extreme immune evasiveness “sets it up to be the principal driver of the next U.S. wave in the weeks ahead,” Topol tweeted Friday.
On Thursday, he told Fortune that scientists won’t know to what extent it challenge vaccines, if it does, until it reaches 30%-50% of cases somewhere.
“It’s not going to wipe out vaccine efficacy, but it could but a dent in protection against hospitalizations and death,” he said.
BQ.1.1 is already known to escape antibody immunity, rendering useless monoclonal antibody treatments used in high-risk individuals with COVID. According to a study last month out of Peking University’s Biomedical Pioneering Innovation Center in China, BQ.1.1 escapes immunity from Bebtelovimab, the last monoclonal antibody drug effective on all variants, as well as Evusheld, which works on some. Along with variants CA.1 and XBB, BQ.1.1 could lead to more severe symptoms, the authors wrote.
BQ.1.1 is one of two variants, including XBB, Topol says should be granted new Greek letter names, like Pi or Rho, because they differ enough from BA.5, the strain they derived from. He also said he would have assigned a Greek letter to BA.5, which was significantly distinct from ancestors BA.1 and BA.2.
The good news, if there is any, about BQ.1 and BQ.1.1 is that new Omicron boosters will “almost certainly” provide “some” protection against them because they were designed to tackle close relative BA.5, Fauci told CBS on Friday.
BQ.1 and BQ.1.1 were first detected in mid-July, according to a Oct. 5 risk assessment from the Ontario, Canada, public health department. It rates the risk level of increased transmissibility, reinfection, and reduced vaccination effectiveness against infection as high, with a high degree of uncertainty.
Some experts, including those at the Institute for Health Metrics and Evaluation at the University of Washington, as well as Fauci, predict a coming wave of infections that will swell this month and peak in late December or early January.
As of Thursday, the seven-day average of cases reported to the CDC sat just under 38,000 a day. With testing at all-time lows, it’s widely accepted that case numbers reported to the agency, and thus reported by it, pale in comparison to the actual number of cases in the U.S.